Literature DB >> 26605035

Acute Dystonia in a Patient with 22q11.2 Deletion Syndrome.

Konstantinos Kontoangelos1, Antonis Maillis1, Maria Maltezou2, Sofia Tsiori3, Charalambos C Papageorgiou1.   

Abstract

The 22q11.2 deletion syndrome (di George syndrome) is one of the most prevalent genetic disorders. The clinical features of the syndrome are distinct facial appearance, velopharyngeal insufficiency, conotruncal heart disease, parathyroid and immune dysfunction; however, little is known about possible neurodegenerative diseases. We describe the case of an 18-year old patient suffering from 22q11.2 deletion syndrome. Since adolescence, he presented with behavioral disorders, recommended treatment with 2 mg aloperidin and he presented cervical dystonia and emergence of torticollis and trunk dystonia. Antipsychotic medications either accelerate or reveal dystonic symptoms.

Entities:  

Keywords:  22q11 deletion syndrome; Velocardiofacial syndrome; dystonia; neuropsychology; psychosis

Year:  2015        PMID: 26605035      PMCID: PMC4620283          DOI: 10.4081/mi.2015.5902

Source DB:  PubMed          Journal:  Ment Illn        ISSN: 2036-7457


Introduction

The 22q11.2 deletion syndrome is one of the most prevalent genetic disorders and has been found to be one of the most common causes of learning disability and mild mental retardation.[1] It is caused by micro deletion in the long arm of chromosome 22 and its clinical characteristics include congenital heart disease; palatal abnormalities; hypocalcaemia and T-cell immunodeficiency; and abnormal faces that include a bulbous nasal tip and prominent nasal root, narrow and with flat cheeks, narrow palpebral fissures, small mouth, receding chin and small cupped ears.[2] Children with 22q11.2 deletion syndrome have been found to have a substantially greater risk for the development of schizophrenia and bipolar disorder with approximately 25-30% presenting psychotic symptoms in adolescence.[3]

Case Report

We describe the case of an 18-year old patient suffering from 22q11.2 deletion syndrome. Since adolescence, he manifested with behavioral disorders, aggression, verbal abuse and sleep disorders. Diagnosis of 22q11.2 was confirmed at the age of 3 with a special chromosomal detector (D22 s75, ONCOR). His performance at school was poor. After a heated argument with his parents, he presented intense anger, started breaking and throwing things and was verbally aggressive. His parents contacted the treating physician, who recommended treatment with 2 mg aloperidin. The patient received treatment dissolved in water. The treatment calmed him down, but a few hours later, he presented with cervical dystonia and emergence of torticollis and trunk dystonia with continuous twisting movements of the trunk and limbs, as well as accompanying dysarthria and pain. The patient visited the emergency outpatient clinic of the hospital, where he was given 1 amp Biperiden i.m. His acute dystonia was considered a side effect of aloperidin administration and he was subsequently subjected to full laboratory testing to investigate the risk factors associated with acute dystonia. The brain magnetic resonance imaging (MRI) revealed no abnormal findings and he was then subjected to a DATscan to investigate a possible dysfunction of the basal ganglia, which proved negative. After two weeks the patient was hospitalized in a psychiatric clinic and was administered quetiapine 200 mg, p.o. This particular treatment improved his clinical picture, without manifesting the usually induced side effects evoked by haloperidol.

Discussion

A literature search was conducted using the Medline computer database. It focused on all studies concerning 22q11.2 deletion syndrome and dystonia. The keywords were selected from titles, abstract and keywords and they were the following: Dystonia parkinsonism and di George syndrome. Butcher et al.[4] suggest that 22q11.2 deletions represent a novel genetic risk factor for early-onset of Parkinson disease (PD) with variable neuropathological presentation reminiscent of LRRK2-associated PD neuropathology. Shulman et al.[5] emphasize that the 22q11.2DS-associated microdeletion affects approximately 30 genes, including several intriguing candidates with potential links to PD pathophysiology. Among the genes in this region is COMT, encoding a key enzyme involved in dopamine catabolism and an established therapeutic target in PD. Zaleski et al.[6] suggest that the genetic of PD is complex. An increased risk to first degree relatives, even in apparently sporadic cases, suggests multifactorial causation of PD. Hereditary forms account for only about 1-3% of all PD cases and tend to have younger age at onset. Mutations in parkin, PINK1 and DJ1 are known to cause autosomal recessive early onset PD and mutations in alpha synuclein, ubiquitin C terminal hydrolase and LRRK2 can cause autosomal dominant PD with variable age of onset. Pinquier et al.[7] report a case of 22q11 deletion in a 17-year-old girl that was initially diagnosed as paranoid schizophrenia. In the case describe, transitory hypocalcemia induced dystonic symptoms that were believed to be catatonic symptoms or neuroleptic secondary effects. Verri et al.[8] describe a new male patient, 33-year-old, with 10p partial deletion affected by hypocalcemia, basal ganglia calcifications and a severe autistic syndrome associated with mental retardation. The patient presented with dysmorphic features and at neurological evaluation, bilateral complete cataract, hypotonia, symptoms have been observed in 14% to 28% of children with di George syndrome and the receipt of antipsychotic treatment increase the risk of dystonic symptoms.[9] Dystonia induced by aloperidin may arise from an imbalance between dopaminergic and muscarinic receptors activity in nigrostriatum in the brain.[10] The possible side effects of antipsychotic medications – either accelerating or reveal dystonic symptoms – merit further study.

Conclusions

Studies of di George syndrome add to the global understanding of the pathophysiology of the neurological symptoms of this common neurodegenerative disease.
  10 in total

1.  Genetics of childhood disorders: XXV. Velocardiofacial syndrome.

Authors:  D Gothelf; P J Lombroso
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2001-04       Impact factor: 8.829

2.  The co-occurrence of early onset Parkinson disease and 22q11.2 deletion syndrome.

Authors:  Christina Zaleski; Anne S Bassett; Karen Tam; Andrea L Shugar; Eva W C Chow; Elizabeth McPherson
Journal:  Am J Med Genet A       Date:  2009-03       Impact factor: 2.802

3.  Structural variation and the expanding genomic architecture of Parkinson disease.

Authors:  Joshua M Shulman
Journal:  JAMA Neurol       Date:  2013-11       Impact factor: 18.302

4.  The neuropsychological phenotype of velocardiofacial syndrome (VCFS): relationship to psychopathology.

Authors:  Renée Lajiness-O'Neill; Isabelle Beaulieu; Alexander Asamoah; Jeffrey B Titus; Erawati Bawle; Saadia Ahmad; John W Kirk; Rebecca Pollack
Journal:  Arch Clin Neuropsychol       Date:  2005-11-22       Impact factor: 2.813

5.  Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications.

Authors:  Nancy J Butcher; Tim-Rasmus Kiehl; Lili-Naz Hazrati; Eva W C Chow; Ekaterina Rogaeva; Anthony E Lang; Anne S Bassett
Journal:  JAMA Neurol       Date:  2013-11       Impact factor: 18.302

6.  [Microdeletion 22q11: apropos of case of schizophrenia in an adolescent].

Authors:  C Pinquier; D Héron; W de Carvalho; G Lazar; P Mazet; D Cohen
Journal:  Encephale       Date:  2001 Jan-Feb       Impact factor: 1.291

7.  Parental origin of the deletion 22q11.2 and brain development in velocardiofacial syndrome: a preliminary study.

Authors:  S Eliez; S E Antonarakis; M A Morris; S P Dahoun; A L Reiss
Journal:  Arch Gen Psychiatry       Date:  2001-01

8.  Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release.

Authors:  Akiko Matsui-Sakata; Hisakazu Ohtani; Yasufumi Sawada
Journal:  Drug Metab Pharmacokinet       Date:  2005-06       Impact factor: 3.614

9.  Chromosome 10p deletion in a patient with hypoparathyroidism, severe mental retardation, autism and basal ganglia calcifications.

Authors:  Annapia Verri; Paola Maraschio; Koen Devriendt; Carla Uggetti; Emanuela Spadoni; Edward Haeusler; Antonio Federico
Journal:  Ann Genet       Date:  2004 Jul-Sep

Review 10.  Psychosis in children with velocardiofacial syndrome (22q11.2 deletion syndrome).

Authors:  Edith M Jolin; Ronald A Weller; Elizabeth B Weller
Journal:  Curr Psychiatry Rep       Date:  2009-04       Impact factor: 5.285

  10 in total
  4 in total

Review 1.  Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: An overview and case series.

Authors:  Nancy J Butcher; Erik Boot; Anthony E Lang; Danielle Andrade; Jacob Vorstman; Donna McDonald-McGinn; Anne S Bassett
Journal:  Am J Med Genet A       Date:  2018-05-19       Impact factor: 2.802

2.  Psychiatric Disorders Associated with 22q11.2 Deletion Syndrome.

Authors:  Orsola Gambini
Journal:  Ment Illn       Date:  2016-06-09

3.  Adverse effects of antipsychotic medication in patients with 22q11.2 deletion syndrome: A systematic review.

Authors:  Janna de Boer; Erik Boot; Lissa van Gils; Therese van Amelsvoort; Janneke Zinkstok
Journal:  Am J Med Genet A       Date:  2019-08-13       Impact factor: 2.802

Review 4.  Insights From Genetic Studies of Cerebral Palsy.

Authors:  Sara A Lewis; Sheetal Shetty; Bryce A Wilson; Aris J Huang; Sheng Chih Jin; Hayley Smithers-Sheedy; Michael C Fahey; Michael C Kruer
Journal:  Front Neurol       Date:  2021-01-21       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.